Michael Andria

570 total citations
15 papers, 408 citations indexed

About

Michael Andria is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Andria has authored 15 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Andria's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer, Lipids, and Metabolism (4 papers) and Cancer Treatment and Pharmacology (4 papers). Michael Andria is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer, Lipids, and Metabolism (4 papers) and Cancer Treatment and Pharmacology (4 papers). Michael Andria collaborates with scholars based in United States, United Kingdom and Australia. Michael Andria's co-authors include Philip J. Gold, Hao Wang, Neal J. Meropol, André Rogatko, Todd Hill, Rebecca Blanchard, Mandeep S. Dhami, Neal J. Meropol, Edith P. Mitchell and Roland Schwarting and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Investigative Dermatology.

In The Last Decade

Michael Andria

15 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Andria United States 6 283 168 68 55 54 15 408
Faye Turner United Kingdom 13 263 0.9× 250 1.5× 71 1.0× 41 0.7× 31 0.6× 15 529
Dawn Colburn United States 10 160 0.6× 252 1.5× 80 1.2× 73 1.3× 35 0.6× 20 524
Paolo Sandri Italy 6 262 0.9× 183 1.1× 38 0.6× 16 0.3× 42 0.8× 14 385
N Dobbs United Kingdom 9 213 0.8× 67 0.4× 82 1.2× 71 1.3× 33 0.6× 12 402
Miki Miyazaki Japan 10 132 0.5× 198 1.2× 38 0.6× 133 2.4× 12 0.2× 20 459
A. Tejerina Spain 11 245 0.9× 151 0.9× 20 0.3× 19 0.3× 32 0.6× 33 398
Sayed Ali Australia 13 307 1.1× 188 1.1× 10 0.1× 18 0.3× 33 0.6× 25 530
Bernie Fitzharris United Kingdom 10 236 0.8× 111 0.7× 16 0.2× 21 0.4× 16 0.3× 11 474
Valerie Relias United States 11 161 0.6× 139 0.8× 29 0.4× 27 0.5× 10 0.2× 32 463
K. Komuta Japan 9 287 1.0× 97 0.6× 12 0.2× 148 2.7× 144 2.7× 19 579

Countries citing papers authored by Michael Andria

Since Specialization
Citations

This map shows the geographic impact of Michael Andria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Andria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Andria more than expected).

Fields of papers citing papers by Michael Andria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Andria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Andria. The network helps show where Michael Andria may publish in the future.

Co-authorship network of co-authors of Michael Andria

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Andria. A scholar is included among the top collaborators of Michael Andria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Andria. Michael Andria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Migden, Michael R., Sunandana Chandra, Guilherme Rabinowits, et al.. (2020). CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncology. 16(4). 11–19. 28 indexed citations
2.
Xu, Yingxin, Chieh-I Chen, Shannon Cope, et al.. (2020). Comparative Efficacy of Cemiplimab Versus Other Systemic Treatments for Advanced Cutaneous Squamous Cell Carcinoma. Future Oncology. 17(5). 611–627. 37 indexed citations
3.
Wei, Wenhui, Michael Andria, Valery Walker, et al.. (2019). A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD). Annals of Allergy Asthma & Immunology. 123(4). 381–388.e2. 34 indexed citations
4.
Ruiz, Emily S., Chieh-I Chen, Yingxin Xu, et al.. (2018). Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy.. Journal of Clinical Oncology. 36(15_suppl). e18703–e18703. 8 indexed citations
5.
Wei, Wenhui, Michael Andria, Valery Walker, et al.. (2017). 204 A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment. Journal of Investigative Dermatology. 137(5). S35–S35. 1 indexed citations
6.
Knopf, Kevin, et al.. (2013). Survival outcomes in U.S. patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 31(4_suppl). 559–559. 1 indexed citations
7.
Knopf, Kevin, et al.. (2013). Survival outcomes in U.S. patients with metastatic colorectal cancer: A retrospective database analysis.. Journal of Clinical Oncology. 31(15_suppl). e14576–e14576. 1 indexed citations
8.
Ferry, David, Tae Won Kim, Tormod Kyrre Guren, et al.. (2013). On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. Journal of Clinical Oncology. 31(4_suppl). 469–469. 2 indexed citations
9.
Mitchell, Edith P., Michael J. Guarino, Carmen J. Allegra, et al.. (2013). North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo (pbo) plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.. Journal of Clinical Oncology. 31(4_suppl). 465–465. 1 indexed citations
10.
Mitchell, Edith P., Michael J. Guarino, Michael Andria, Pankaj Bhargava, & Jeffrey J. Kirshner. (2013). North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.. Journal of Clinical Oncology. 31(15_suppl). e14528–e14528. 1 indexed citations
11.
Ferry, David, Tae Won Kim, Tormod Kyrre Guren, et al.. (2013). On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. Journal of Clinical Oncology. 31(15_suppl). 3573–3573. 3 indexed citations
12.
Iqbal, Sheikh Usman, et al.. (2012). Current practices in 1st- (1L), 2nd- (2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). e14028–e14028. 1 indexed citations
13.
Meropol, Neal J., Philip J. Gold, Robert B. Diasio, et al.. (2006). Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 24(25). 4069–4077. 87 indexed citations
14.
Meropol, Neal J., Michael Andria, Todd Hill, et al.. (2005). UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan. Clinical Cancer Research. 11(3). 1226–1236. 202 indexed citations
15.
Andria, Michael, et al.. (1999). Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants. American Journal of Health-System Pharmacy. 56(2). 161–164. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Faye Turner Breakdown of academic impact, for papers by Dawn Colburn Breakdown of academic impact, for papers by Paolo Sandri Breakdown of academic impact, for papers by N Dobbs Breakdown of academic impact, for papers by Miki Miyazaki Breakdown of academic impact, for papers by A. Tejerina Breakdown of academic impact, for papers by Sayed Ali Breakdown of academic impact, for papers by Bernie Fitzharris Breakdown of academic impact, for papers by Valerie Relias Breakdown of academic impact, for papers by K. Komuta
Rankless by CCL
2026